USD 0.03
(6.67%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 53.96 Million USD | -59.56% |
2022 | 133.44 Million USD | -21.41% |
2021 | 169.79 Million USD | -11.81% |
2020 | 192.53 Million USD | 82.58% |
2019 | 105.45 Million USD | 306.41% |
2018 | 25.94 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 41.66 Million USD | -22.78% |
2024 Q2 | 35.47 Million USD | -14.87% |
2023 Q3 | 84.72 Million USD | -15.52% |
2023 FY | 53.96 Million USD | -59.56% |
2023 Q4 | 53.96 Million USD | -36.31% |
2023 Q2 | 100.29 Million USD | -13.54% |
2023 Q1 | 115.99 Million USD | -13.07% |
2022 Q3 | 114.62 Million USD | -17.14% |
2022 Q2 | 138.33 Million USD | 5.08% |
2022 Q1 | 131.64 Million USD | -22.47% |
2022 FY | 133.44 Million USD | -21.41% |
2022 Q4 | 133.44 Million USD | 16.41% |
2021 Q2 | 140.59 Million USD | -13.19% |
2021 FY | 169.79 Million USD | -11.81% |
2021 Q1 | 161.94 Million USD | -15.89% |
2021 Q4 | 169.79 Million USD | -14.0% |
2021 Q3 | 197.42 Million USD | 40.42% |
2020 Q2 | 72.02 Million USD | -17.31% |
2020 FY | 192.53 Million USD | 82.58% |
2020 Q1 | 87.1 Million USD | -17.4% |
2020 Q4 | 192.53 Million USD | -9.4% |
2020 Q3 | 212.5 Million USD | 195.03% |
2019 FY | 105.45 Million USD | 306.41% |
2019 Q4 | 105.45 Million USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | 25.94 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Biotricity, Inc. | 5.94 Million USD | -808.016% |
Cell MedX Corp. | 46.12 Thousand USD | -116894.059% |
Dynatronics Corporation | 25.94 Million USD | -108.014% |
Nemaura Medical Inc. | 14.56 Million USD | -270.522% |
PetVivo Holdings, Inc. | 3.11 Million USD | -1632.123% |
RetinalGenix Technologies Inc. | 156.00 USD | -34589643.59% |
Sonendo, Inc. | 78.16 Million USD | 30.962% |
Telesis Bio, Inc. | 70.41 Million USD | 23.364% |
Talis Biomedical Corporation | 98.34 Million USD | 45.129% |
Viveve Medical, Inc. | 25.91 Million USD | -108.235% |